Viewing

News

Ceeable, a web-based, mobile digital technology designed to detect early-stage eye diseases-an innovation that can help shape 21st century medicine-was awarded third place in the American Medical Association’s inaugural Healthier Nation Innovation Challenge.

With an estimated 19 million annual operations, cataract surgery is the most common surgical procedure in the world. According to the World Health Organization, the number of worldwide cataract surgeries is expected to increase to 32 million by 2020, in large part due to the aging of the population.

Uveitis presents particular problems for ophthalmologists. Inflammation inside the eye can occur from so many causes that the diagnosis often requires painstaking, time-consuming investigation. As researchers have learned more about the disease, the possible etiologies and treatments have multiplied.

Because there are no proven treatments to prevent the progression of keratoconus, corneal crosslinking (CXL) is attractive as a viable alternative to keratoplasty and other surgical procedures, with impressive early results.

Change is an inside job. Are you unhappy with your practice’s growth? Take the often overlooked option of offensive time management. Actively shape your day by establishing what I like to call selective control.

A visit to two innovative optical shops reveals differing portraitures of providing better customer experience and increasing capture rate.

The combination of phenylephrine and ketorolac helped maintain pupil diameter and lowered postoperative pain compared with placebo in patients having cataract surgery in two pooled phase III studies.

Surgical draping for ophthalmic surgery has never been quick or easy-until now. A new drape design allows the surgeon or scrub nurse to fully drape the patient in seconds.

Intracameral administration of the fixed combination of phenylephrine and ketorolac injection 1%/0.3% (Omidria, Omeros) during cataract surgery is safe and effective for maintaining pupil dilation, and minimizes the need for a pupil expansion device, according to the findings of a retrospective study conducted by Frank A. Bucci, Jr., MD.

The U.S. IDE clinical trial of the investigational extended range of vision IOL (Model ZXR00; Tecnis Symfony Extended Range of Vision IOL, Abbott Medical Optics) found that the implant delivered a full range of uncorrected vision and minimized or eliminated the need for spectacle wear in most patients.

In a multicenter trial including 162 eyes undergoing cataract surgery with implantation of a variety of IOL types, use of intraoperative aberrometry to guide IOL spherical power selection minimized residual refractive error.

By just about anybody's definition of success, ophthalmologists are successful: intelligent, well-paid, able to make people’s lives better and held in high esteem by the public. Not to mention good-looking. So they must be happy-right? Not necessarily.

Ophthalmologists have been waiting more than a decade for a new treatment option for their dry eye patients-and the anticipation is finally over. Lifitegrast ophthalmic solution 5% (Xiidra, Shire Ophthalmics) is a twice-daily eye drop solution and is the only FDA-approved drug indicated to treat the signs and symptoms of dry eye disease, according to the company.